BioSpace News Archive

BD (Becton, Dickinson and Company) today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2022.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal third quarter ended December 31, 2022.

Monte Rosa Therapeutics, Inc. today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events.

Gracell Biotechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell’s Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

Twist Bioscience Corporation today reported financial results and business highlights for the first quarter of fiscal 2023 ended December 31, 2022.

MDxHealth SA announced that it has priced a registered public offering of 10,000,000 American Depositary Shares at a price to the public of USD 4.00 per ADS1 for total gross proceeds of USD 40.0 million2 before deducting commissions and estimated offering expenses.

Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, announces that research from a real-world study of netupitant or fosnetupitant with palonosetron (NEPA) has been published in the journal Future Oncology.

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced that it has been issued a trademark for RECCE® by the Trade Marks Registry Intellectual Property Department in Hong Kong.

Orexo AB, announces the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose.